AlphAIAlphAI — Financial news for AI agents
finance.yahoo.com$GH

Guardant Health Shares Fall 5.5% as Higher Cash Burn Forecast Overshadows Strong Q3 Revenue Growth

Guardant Health (GH) shares fell 5.5% premarket after Q3 2026 results beat estimates but raised full-year cash burn forecast. Revenue grew 36% YoY to $361M, adjusted loss narrowed to $0.29 per share. Full-year revenue guidance raised to $1.36B-$1.37B. Higher operating expenses and cash burn concerns overshadowed positive results.

Original reporting
finance.yahoo.com
Published Nov 6, 2026, 11:22 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 6, 2026, 11:38 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Guardant Health Shares Fall 5.5% as Higher Cash Burn Forecast Overshadows Strong Q3 Revenue Growth — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$GHBearishHigh
01

Why it matters

The guidance revision dominates market reaction, causing a pre‑market sell‑off despite earnings beat.

02

Market read

The earnings release introduces new guidance that materially changes the company's cash outlook, prompting immediate price action.

03

What to watch

Potential future partnerships or reimbursement improvements could offset cash‑burn concerns.

Relevance 8/10Novelty 8/10Timing: premarket today

Background

Guardant Health reported Q3 2026 results with revenue up 36% YoY and a narrower loss, but raised its free cash‑flow burn forecast.

Company-level read

Ticker impact

$GHBearishHigh confidence
Context

Q3 2026 earnings beat but guidance raised full-year free cash flow burn to $205‑$220M, triggering a 5.5% pre‑market drop.

Expected impact

downward pressure as market absorbs higher cash‑burn guidance

Evidence & confidence

Revenue beat is outweighed by the raised cash‑burn outlook, a material change to the company's financial outlook.

Market effects

Sector

May weigh on other precision‑oncology and biotech stocks as cash‑burn concerns rise.

Regional

Limited to US biotech sector; broader market remains positive.

Global

Minimal beyond US biotech investors.

Counterpoint

What could challenge this read

Revenue growth remains strong; investors could view the cash‑burn increase as temporary and buy on dip.

Key entities

  • company
    Guardant Health

    Precision oncology firm reporting Q3 results.

Read at source← All news

StoryGuardant Health posts strong Q3 revenue growth but raises full‑year cash‑burn outlook

Also covered by

4 outlets

Related articles

$GHHighAI 8/10

Guardant Health stock reiterated at Buy by BTIG after Q3 beat

BTIG reiterated a Buy rating on Guardant Health (GH) with a $210 price target after Q3 results. GH beat revenue estimates by 3% and raised 2026 guidance. Shares fell 5% in after-hours trading. The company reported 36% revenue growth and adjusted earnings of -$0.29 per share, better than expected. BTIG noted strong growth in oncology and screening businesses, designating GH as a Top Pick.

investing.com
$GHHighAI 8/10

Why is Guardant Health stock sliding today?

Guardant Health (GH) shares fell 5.5% premarket after Q3 2026 results showed revenue of $361M (up 36% YoY) and EPS of -$0.29 (beating estimates). The stock declined due to increased full-year free cash flow burn guidance of $205M-$220M, up from $195M-$205M. Revenue guidance was raised to $1.36B-$1.37B, in line with consensus.

investing.com
$GHHighAI 8/10

Guardant Health (GH) Q3 2026 Earnings Call Transcript

Guardant Health (GH) reported Q3 2026 revenue growth of 36% to $361M. Oncology revenue rose 25% to $231M, with test volumes up 58%. The company received FDA approval for Guardant360 CDx as a companion diagnostic for AstraZeneca's ETCAMAH, and submitted a PMA application for Guardant360 Tissue. They also announced the launch of 11 new Smart Apps for Guardant360 Liquid.

finance.yahoo.com
$GHMed

Guardant Health Inc (GH) (Q3 2026) Earnings Call Highlights: Revenue Surges 36%

Guardant Health (GH) reported a 36% revenue surge in Q3 2026. Free cash flow burn guidance increased to $205-$220M due to CMS delays. Non-GAAP operating expenses rose 26% to $287M. Shield ASP may decrease short-term due to patient mix shifts. Reveal Ultra launch is planned for year-end, but Medicare coverage is pending. The company faces reimbursement challenges for quarterly ESR1 testing.

finance.yahoo.com
$GHHighAI 8/10

What Guardant Health (GH) Said on Its Q3 Earnings Call

Guardant Health (GH) reported Q3 earnings, with oncology revenue up 25% to $231M and test volume rising 58%. Shield's average selling price was above $800, with expectations of short-term decline. The company maintained its 2026 outlook for 30% oncology revenue growth and now expects over 50% volume growth. Non-GAAP gross margin improved to 67%, and adjusted EBITDA loss narrowed to $37M. Guardant also highlighted FDA approvals and plans for new product launches.

finance.yahoo.com